Log in to search using one of your social media accounts:

 

Prostate Cancer Symptoms Aren't Always Obvious
Warning signs often confused with other conditions (Source: WebMD Health)
Source: WebMD Health - September 20, 2017 Category: Consumer Health News Source Type: news

BMJ: Multiparametric MRI has role in prostate screening
Thanks to recent research demonstrating its high sensitivity and negative predictive...Read more on AuntMinnie.comRelated Reading: MRI can replace biopsy for prostate cancer surveillance MRI can help avoid unnecessary prostate cancer biopsies Prostate CAD boosts detection for most readers NPV is a key indicator for future prostate cancer risk Abstinence before prostate MRI offers benefits in over 60s (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 20, 2017 Category: Radiology Source Type: news

Prostate Cancer Symptoms Aren ’ t Always Obvious
Warning signs often confused with other conditions (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2017 Category: Cancer & Oncology Tags: Oncology, Reproductive Medicine, Urology, Geriatrics, News, Source Type: news

Prostate Cancer Symptoms Aren't Always Obvious
Warning signs often confused with other conditions Source: HealthDay Related MedlinePlus Pages: Men's Health, Prostate Cancer, Prostate Cancer Screening (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 20, 2017 Category: Consumer Health News Source Type: news

Prostate Cancer Symptoms Aren't Always Obvious
WEDNESDAY, Sept. 20, 2017 -- Although about 1 in 7 men will be eventually be diagnosed with prostate cancer in his lifetime, the warning signs of the disease are often vague and may be confused with other conditions, experts at Fox Chase Cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 20, 2017 Category: General Medicine Source Type: news

Prostate cancer breakthrough: THIS finding could pave way for new treatment
PROSTATE cancer is the most common form of cancer among men in the UK - and can be symptomless, making the disease even more difficult to treat. (Source: Daily Express - Health)
Source: Daily Express - Health - September 20, 2017 Category: Consumer Health News Source Type: news

National Cancer Institute designates UCLA brain cancer program a site of research excellence
The brain cancer program at UCLA ’s Jonsson Comprehensive Cancer Center and the UCLA Brain Tumor Center has been designated a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute, making it one of only five brain cancer programs nationwide to receive this national recognition and substantial rese arch funding.The designation comes with an $11.4 million, five-year grant that recognizes UCLA ’s brain cancer program as one of the best in the country. The program supports research into the prevention, detection and treatment of one of the most lethal and deadly cancers, which often...
Source: UCLA Newsroom: Health Sciences - September 20, 2017 Category: Universities & Medical Training Source Type: news

Prostate Cancer Symptoms Aren't Always Obvious
Warning signs often confused with other conditions (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Former SEC Commissioner Mike Slive on his latest venture
Then new organization intends to spearhead innovations in the cure for Prostate Cancer (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 19, 2017 Category: American Health Authors: Tyler Patchen Source Type: news

Former SEC Commissioner Mike Slive on his latest venture
Then new organization intends to spearhead innovations in the cure for Prostate Cancer (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 19, 2017 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Qiagen Partners with Cell Diagnostics Company
ANGLE plc, a liquid biopsy company, has secured a valuable partnership with molecular testing giant Qiagen and an exclusive option agreement with Queen Mary University of London. ANGLE is known for Parsortix, its novel system for capturing and harvesting circulating tumor cells (CTCs) from blood. A Large Selling Opportunity with Qiagen The co-marketing partnership with Qiagen isn’t just a major win for ANGLE—it will also give Qiagen, which has more than 500,000 customers, an additional opportunity in the liquid biopsy space and the ability to offer ANGLE’s unique CTC harvesting technology alongside its ow...
Source: MDDI - September 19, 2017 Category: Medical Devices Authors: Marie Thibault Tags: IVD Source Type: news

Futile: Prostate Cancer Vaccine Phase 3 Trial Ends Futile: Prostate Cancer Vaccine Phase 3 Trial Ends
Prostvac is an immunotherapy designed to induce T-cell responses and thus kill prostate cancer cells. As a monotherapy, it is not effective.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

When PCPs Help Patients Choose Prostate Cancer Treatment When PCPs Help Patients Choose Prostate Cancer Treatment
When it comes to guiding patients in prostate cancer treatment options, what do PCPs need to know?Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Charities unite to award $2.5 million for breast and prostate cancer research
(University of Adelaide) Leading Australian cancer researcher Professor Wayne Tilley has today been presented with a $2.5 million Breast& Prostate Cancer Linkage Grant, thanks to a groundbreaking collaboration between the National Breast Cancer Foundation (NBCF) and the Movember Foundation in Australia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2017 Category: International Medicine & Public Health Source Type: news

Wimbledon star John Lloyd: 'Getting prostate cancer was a real wake-up call'
THE moment that Andy Murray created history by beating Canadian player Milos Raonic in straight sets, winning Wimbledon for a second time in 2016, will be etched in the memory of British tennis fans for ever. (Source: Daily Express - Health)
Source: Daily Express - Health - September 18, 2017 Category: Consumer Health News Source Type: news

FDG-PET/CT contributes to anal cancer follow-up
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 15, 2017 Category: Radiology Source Type: news

Pfizer and Astellas report positive Phase III data from prostate cancer trial
Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta … (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA ® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA ® in Combination with Prednisone and Androgen Deprivation Therapy (ADT) (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 14, 2017 Category: Pharmaceuticals Source Type: news

Pfizer, Astellas prostate cancer drug promising in late-stage trial
(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial NEW YORK and TOKYO, Sept. 14, 2017 -- (H... Biopharmaceuticals, Oncology Astellas Pharma, Pfizer, XTANDI, enzalutamide, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2017 Category: Pharmaceuticals Source Type: news

Pfizer, Astellas prostate cancer drug succeeds key trial
(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer, Astellas prostate cancer drug clears late-stage trial
(Reuters) - Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer, Astellas prostate cancer drug clears late-stage trial
(Reuters) - Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Improving the way we assign prostate cancer treatment
(Norwegian University of Science and Technology) Many patients are treated for prostate cancer unnecessarily. Norwegian researchers are working to reduce overtreatment of prostate cancer while at the same time trying to detect the most high-risk patients. They've just been awarded EUR 1.5 million in EU support. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 14, 2017 Category: Biology Source Type: news

FDG-PET/CT contributes to anal cancer follow-up assessment
Given its high sensitivity and negative predictive value, French researchers...Read more on AuntMinnie.comRelated Reading: AI algorithm can classify bone lesions on PET/CT images FDG-PET/CT foretells melanoma therapy response New PET tracer could work well for prostate cancer SNMMI: PET/CT with prostate agent changes therapy plans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 13, 2017 Category: Radiology Source Type: news

Edap submits new FDA 510(k) for Focal One HIFU
Edap (NSDQ:EDAP) said today it submitted a new FDA 510(k) application for its next-gen high-intensity focused ultrasound Focal One device designed to treat prostate cancer after withdrawing its previous application in July. The new application alllowed the France-based company to include a new set of clinical data, which it had decided to include following “advanced discussions” with the FDA earlier this year. “The new 510k review may be more efficient as the updates only pertain to the clinical section which includes new studies from active and academic Focal One centers in Europe. Our regulato...
Source: Mass Device - September 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Ultrasound EDAP TMS SA Source Type: news

New Study Finds PSA Screening Reduces Deaths-- Is It Valid? New Study Finds PSA Screening Reduces Deaths-- Is It Valid?
Dr Kenny Lin looks critically at recent statistical modeling data that he believes may set back prostate cancer care.Georgetown University Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 12, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news

Prostate cancer symptoms: Three warning signs you could be missing
PROSTATE cancer can be symptomless - but often there are warning signs which can give men an indicator they should see their GP. (Source: Daily Express - Health)
Source: Daily Express - Health - September 12, 2017 Category: Consumer Health News Source Type: news

Genomic Testing for Localized Prostate Cancer Genomic Testing for Localized Prostate Cancer
What role might currently available genetic testing options have in the risk stratification of localized prostate cancer?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Stop prostate cancer dead in its tracks by eating apples and grapes, reveals new research
(Natural News) Eating apples and grapes may help stave off prostate cancer onset, the most common cancer among American men. As reported by Nature.com, a study published on Precision Oncology revealed that a combination of nutritional compounds can inhibit cancer cell growth. As part of the study, a team of researchers at the University of Texas at... (Source: NaturalNews.com)
Source: NaturalNews.com - September 8, 2017 Category: Consumer Health News Source Type: news

7 medtech stories we missed this week: Sept. 8, 2017
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2017 Category: Pharmaceuticals Source Type: news

Patients with high risk prostate cancer may benefit 'equally' from two new treatments
(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

Your NEJM Group Today: Postprandial Acute Chest Pain Case / Mortality Benefits of Prostate Cancer Screening? / Maine Family Medicine Opportunity (FREE)
By the Editors Take a look at today's offering from NEJM Group:NEJM Clinical Practice Center: Case Record: A 32-year-old man presented to the emergency department for the abrupt onset … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 8, 2017 Category: Primary Care Source Type: news

No Difference in Toxicity for 6 - , 2 - Fraction HDR in Prostate Cancer
Urinary, sexual toxicity similar with 6 - , 2 - fraction high - dose - rate brachytherapy regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 7, 2017 Category: Cancer & Oncology Tags: Oncology, Radiology, Urology, Journal, Source Type: news

Re-Analysis Finds Benefit In Cancer Screening. Should You Believe It?
A striking paper observes that routine blood testing for prostate specific antigen lowered men ’s risk of dying from prostate cancer by 25%-32%. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 7, 2017 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Source Type: news

Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Eligible Patients Can Use the myRisk® Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members SALT LAKE CITY, Sept. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (NASDAQ:... Diagnostics, Oncology Myriad Genetics, hereditary cancer risk assessment, myRisk, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2017 Category: Pharmaceuticals Source Type: news

AI algorithm can classify bone lesions on PET/CT images
An artificial intelligence (AI) algorithm can reliably classify benign and...Read more on AuntMinnie.comRelated Reading: Hybrid modalities disappoint in bone metastases accuracy How to develop deep-learning algorithms for radiology AI can obviate biopsies of indolent thyroid nodules Luminal water MRI could be best for prostate cancer CAD finds vertebral lung cancer metastases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 7, 2017 Category: Radiology Source Type: news

Double targeting ligands to identify and treat prostate cancer
(Society of Nuclear Medicine) Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The study is presented in the featured basic article of the September issue of the Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2017 Category: Cancer & Oncology Source Type: news

More Older Men Get Prostate Radiation When Docs Own Equipment More Older Men Get Prostate Radiation When Docs Own Equipment
Elderly men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even patients who may be too old to benefit from the treatment, a U.S. study suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 6, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system
Lumicell said today that it is launching clinical studies in breast cancer and prostate cancer with its Lum image-guided cancer surgery system. The breast cancer trial is a pivotal study following an initial training period with surgeons, the Wellesley, Mass.-based company reported, and the prostate cancer study is a first for Lumicell and its technology. Get the full story at our sister site, Drug Delivery Business News. The post Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Surgical Lumicell Source Type: news

Dementia Risk Not Higher in ADT-Treated Prostate CA Patients Dementia Risk Not Higher in ADT-Treated Prostate CA Patients
In contrast to previous reports, a new study found no increased risk for Alzheimer ’ s disease or dementia among men receiving androgen deprivation therapy (ADT) for prostate cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Fighting Prostate Cancer With Abundant Treatment Options
A diagnosis of prostate cancer can feel overwhelming for a man. Foremost on their mind is usually what’s the best way to (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - September 5, 2017 Category: Consumer Health News Source Type: news

Prostate Cancer: Symptoms, Tests, and Treatment
September is Prostate Health Awaremeness month. Prostate cancer is the second most common cause of cancer-related deaths among American men. Learn more. (Source: FDA Consumer Health Information Updates)
Source: FDA Consumer Health Information Updates - September 5, 2017 Category: Consumer Health News Source Type: news

Studies may boost PSA screening for prostate cancer
Analysis of 2 major trials on the prostate cancer screening test shows it cuts men's risk of dying from the disease (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 5, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Prostate cancer: Could a breast cancer drug reduce recurrence?
Researchers have found that PARP inhibitors - a class of drugs used to treat breast cancer - may also benefit men with prostate cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 5, 2017 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

New Research Finds Value in PSA Testing
Analysis of 2 major trials on the prostate cancer screen shows it cuts men's risk of dying from the disease (Source: WebMD Health)
Source: WebMD Health - September 5, 2017 Category: Consumer Health News Source Type: news

PSA Screening Does Reduce Deaths, New Analysis Shows PSA Screening Does Reduce Deaths, New Analysis Shows
A new analysis of data from the PLCO and the ERSPC screening trials found that both studies show that PSA screening reduces death from prostate cancer.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Research Finds Value in PSA Testing
Analysis of 2 major trials on the prostate cancer screen shows it cuts men's risk of dying from the disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 5, 2017 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Urology, Preventive Medicine, News, Source Type: news